Jha Nisha, Rathore Devendra Singh, Shankar P Ravi, Gyawali Sudesh, Alshakka Mohamed, Bhandary Shital
KIST Medical College, Lalitpur, Nepal.
L.R. Institute of Pharmacy, Solan, India.
Australas Med J. 2014 Dec 31;7(12):478-89. doi: 10.4066/AMJ.2014.2235. eCollection 2014.
Pharmacovigilance concerns the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. Consumer pharmacovigilance is the involvement of consumers in adverse drug reaction (ADR) reporting. Assessing healthcare professionals' (HCPs) knowledge of and attitude towards pharmacovigilance and consumer pharmacovigilance is integral to strengthening adverse drug reaction reporting systems.
To study knowledge of and attitude towards pharmacovigilance and consumer pharmacovigilance among HCPs from KIST Medical College, Lalitpur, Nepal, and to plan an appropriate educational intervention to address deficiencies noted.
The study was conducted from February 2013 to December 2013 at KIST Medical College using a self-administered, pretested, structured questionnaire. The maximum possible scores for knowledge, attitude, and total were 100, 95, and 195, respectively. Baseline knowledge and attitude were studied. Two months after the questionnaire, an intervention that used a combination of methods about pharmacovigilance and consumer pharmacovigilance was undertaken. Knowledge and attitudes were studied immediately after the intervention. Scores before and after the intervention were compared using Wilcoxon signed-rank test.
A total of 105 HCPs participated. The median (interquartile range) knowledge, attitude, and total scores before the intervention were 56 (7), 72 (9), and 127 (16), respectively. After the intervention the scores increased significantly to 72 (8), 75 (11.5), and 146 (16.5) (p<0.001), respectively.
The intervention was effective in improving HCPs' knowledge of and attitude towards pharmacovigilance and consumer pharmacovigilance. More studies on this topic among HCPs at other institutions and in the community are required.
药物警戒涉及不良反应或任何其他与药物相关问题的发现、评估、理解及预防。消费者药物警戒是指消费者参与药品不良反应（ADR）报告。评估医疗保健专业人员（HCPs）对药物警戒和消费者药物警戒的知识及态度对于加强药品不良反应报告系统至关重要。
研究尼泊尔拉利特布尔基斯特医学院的医疗保健专业人员对药物警戒和消费者药物警戒的知识及态度，并规划适当的教育干预措施以解决所发现的不足。
2013年2月至2013年12月在基斯特医学院开展该研究，使用自行填写、经过预测试的结构化问卷。知识、态度及总分的最高可能分数分别为100分、95分和195分。对基线知识和态度进行研究。在问卷调查两个月后，开展了一项结合药物警戒和消费者药物警戒多种方法的干预措施。干预措施结束后立即研究知识和态度。使用Wilcoxon符号秩检验比较干预前后的分数。
共有105名医疗保健专业人员参与。干预前知识、态度及总分的中位数（四分位间距）分别为56（7）、72（9）和127（16）。干预后分数显著提高，分别为72（8）、75（11.5）和146（16.5）（p<0.001）。
该干预措施有效提高了医疗保健专业人员对药物警戒和消费者药物警戒的知识及态度。需要在其他机构和社区的医疗保健专业人员中开展更多关于该主题的研究。
